Russia facing shortage of drugs against rheumatoid arthritis

15 December 2021

The widespread use of drugs for autoimmune diseases against COVID-19 in Russia has led to a decrease in the availability of these drugs among patients with rheumatoid arthritis and forced them to buy these drugs at their own expense.

According to pharma analytics firm DSM Group, sales of 19 drugs for the treatment of autoimmune diseases, including rheumatoid arthritis, in the first ten months of this year grew 22.7% year-on-year, to 2.86 billion roubles ($38.7 million).

The biggest growth was observed for drugs based on dexamethasone (+54%), methylprednisolone - by 34%, prednisolone - by 30%. In January-October, sales of the expensive Xeljanz (tofacitinib), produced by Pfizer (NYSE: PFE), increased by 165%, with an average cost of 49,000 roubles ($667) per package.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical